Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Azacitidine 12Cyclophosphamide 10venetoclax 8fludarabine phosphate 7fludarabine 7Whole-Body Irradiation 7Biopsy 7Specimen Handling 6Mycophenolic Acid 6Injections 6Decitabine 6Tacrolimus 5Cytarabine 5Busulfan 5decitabine and cedazuridine drug combination 4Stem Cell Transplantation 4Peripheral Blood Stem Cell Transplantation 4Cyclosporine 4cedazuridine 3X-Rays 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3olutasidenib 2Vorinostat 2Sirolimus 2Rituximab 2Melphalan 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Idarubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × seclidemstat × 90 days × Clear all
NCT04734990 2026-04-02

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
24 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡